CD4 lymphopenia to identify end-of-life metastatic cancer patients

European Journal of Cancer

Volumn 49, Issue 5, 2013, Pages 1080-1089

  Péron, Julien ^a,b,c,d   Cropet, Claire ^d   Tredan, Olivier ^d   Bachelot, Thomas ^d   Ray Coquard, Isabelle ^d   Clapisson, Gilles ^d   Chabaud, Sylvie ^d   Philip, Irene ^d   Borg, Christophe ^e   Cassier, Philippe ^d   Labidi Galy, Inthidar ^d   Sebban, Catherine ^d   Perol, David ^d   Biron, Pierre ^d   Caux, Christophe ^d   Menetrier Caux, Christine ^d   Blay, Jean Yves ^d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Cancer; CD4 lymphocytes; Immunology; Lymphopenia; Survival analysis

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LIFE EXPECTANCY; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; MYELOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL RATE; TERMINAL CARE; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INCIDENCE; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84874941830     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.003     Document Type: Article

References (36)

1. S. Aggarwal, S. Gollapudi, and S. Gupta Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases J Immunol 162 1999 2154 2161
2. J.Y. Blay, S. Negrier, and V. Combaret Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma Cancer Res 52 1992 3317 3322
3. G. Dworacki, N. Meidenbauer, and I. Kuss Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma Clin Cancer Res 7 2001 947s 957s
4. T. Saito, I. Kuss, and G. Dworacki Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer Clin Cancer Res 5 1999 1263 1273
5. J. Nunez, J. Sanchis, and V. Bodi Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levels Atherosclerosis 206 2009 251 257
6. M.S. Dennis, A. Nicolson, and A.B. Lehmann Clinical associations of lymphopenia in elderly persons admitted to acute medical and psychiatric wards Gerontology 44 1998 168 171
7. D. Hasenclever, and V. Diehl A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease N Engl J Med 339 1998 1506 1514
8. M. Siddiqui, K. Ristow, and S.N. Markovic Absolute lymphocyte count predicts overall survival in follicular lymphomas Br J Haematol 134 2006 596 601
9. G. De Angulo, M. Hernandez, and J. Morales-Arias Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma J Pediatr Hematol Oncol 29 2007 48 52
10. I. Ray-Coquard, C. Cropet, and M. Van Glabbeke Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas Cancer Res 69 2009 5383 5391
11. C. Moore, D. Eslin, and A. Levy Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma Pediatr Blood Cancer 55 6 2010 1096 1102
12. N. Ceze, G. Thibault, and G. Goujon Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy Cancer Chemother Pharmacol 68 5 2011 1305 1313
13. Y.R. Kim, J.S. Kim, and S.J. Kim Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy J Hematol Oncol 4 2011 34
14. J.Y. Blay, F. Chauvin, and A. Le Cesne Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia J Clin Oncol 14 1996 636 643
15. C.W. Choi, H.J. Sung, and K.H. Park Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia Am J Hematol 73 2003 263 266
16. A. Oguz, C. Karadeniz, E.C. Ckitak, and V. Cil Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia? Pediatr Hematol Oncol 23 2006 143 151
17. I. Ray-Coquard, C. Borg, and T. Bachelot Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy Br J Cancer 88 2003 181 186
18. C. Borg, I. Ray-Coquard, and I. Philip CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer Cancer 101 2004 2675 2680
19. J.Y. Blay, A. Le Cesne, and C. Mermet A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy Blood 92 1998 405 410
20. I. Ray-Coquard, A. Le Cesne, and M.T. Rubio Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group J Clin Oncol 17 1999 2840 2846
21. P. Biron, I. Ray-Coquard, and A. Le Cesne ELYPSE 2: a prospective randomized trial comparing filgrastim (G-CSF) in primary and secondary prophylaxis in patients (pts) at high risk for febrile neutropenia (FN) [2006 ASCO Annual Meeting Proceedings Part I] J Clin Oncol 24 18S 2006 8614
22. I. Ray-Coquard, S. Dussart, and C. Goillot A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group Ann Oncol 20 2009 1105 1112
23. I. Ray-Coquard, H. Ghesquiere, and T. Bachelot Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas Br J Cancer 85 2001 816 822
24. Y. Oki, K. Yamamoto, and H. Kato Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab Eur J Haematol 81 2008 448 453
25. A. Plonquet, C. Haioun, and J.P. Jais Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma Ann Oncol 18 2007 1209 1215
26. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
27. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
28. A. Lortholary, M. Cary-Ten Have Dallinga, and C. El Kouri Paclitaxel-induced lupus Presse Med 36 2007 1207 1208
29. O.T. Manuarii Manuel, T. Bachelot, and T. Rabeony Low TCR diversity (divpenia) is a new prognosis factor of overall survival in metastatic breast cancer AACR 2011 [abstract number: LB-165]
30. R.J. Biggar, E.A. Engels, and S. Ly Survival after cancer diagnosis in persons with AIDS J Acquir Immune Defic Syndr 39 2005 293 299
31. E.J. Fordyce, T.P. Singh, and D. Nash Survival rates in NYC in the era of combination ART J Acquir Immune Defic Syndr 30 2002 111 118
32. I.D. Davis, B. Brady, and R.F. Kefford Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial Clin Cancer Res 15 2009 2123 2129
33. C.L. Mackall, T.J. Fry, and R.E. Gress Harnessing the biology of IL-7 for therapeutic application Nat Rev Immunol 11 5 2011 330 342
34. C. Menard, F. Ghiringhelli, and S. Roux Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14 2008 5242 5249
35. S. Azzi, S. Bruno, and J. Giron-Michel Differentiation therapy: targeting human renal cancer stem cells with interleukin 15 J Natl Cancer Inst 103 24 2011 1884 1898
36. O. Tredan, I. Ray-Coquard, and F. Chvetzoff Validation of prognostic scores for survival in cancer patients beyond first-line therapy BMC cancer 80 2011 5875 5885